Zymeworks (ZYME) shares slumped 46% pre-bell Tuesday, adding to Monday's losses.
Arvinas (ARVN) shares retreated 41% after the company and Pfizer (PFE) said their phase 3 trial of vepdegestrant for the treatment of breast cancer failed to reach statistical significance in improvement in progression free survival in the intent-to-treat population.
Evolus (EOLS) shares fell 36% after Monday's 6.6% loss.
Stoke Therapeutics (STOK) shares decreased 36% following a muted session.
Medallion Financial (MFIN) shares were down 32% after a 2.4% gain in the previous session.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.